- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Nicola Hanania: Treatment of T2-High Asthma Is Constantly Evolving
Treatment targets include several interleukins, immunoglobulin E, and alarmins, pointed out Nicola Hanania, MD, MS, pulmonary critical care physician and director, Airway Clinical Research Center, Baylor College of Medicine, Houston.
Treatment targets for this type of asthma include interleukins 4, 5, and 13, as well as immunoglobulin E and alarmins, but unmet needs remain, pointed out Nicola Hanania, MD, MS, pulmonary critical care physician and director, Airway Clinical Research Center, Baylor College of Medicine, Houston, Texas.
Transcript
What recent advancements in therapy for T2-high asthma look most promising?
Well, the nice thing about T2-high asthma is that we have identified several targets. We know at least the cytokines, chemokines, and receptors that drive this type of asthma. Of course, it's an evolving field, so we can't claim we know everything.
I talked about the anti-IL-5s [interleukin-5]. IL-5 is an important cytokine. IL-4 and IL-13 are very important cytokines; these are effector cytokines. And then IgE [immunoglobulin E]. These are the ones that now we are targeting. However, there are others.
We have a set of cytokines called alarmins. The alarmins are important cytokines because they drive the inflammatory cascade from right below the epithelium. So one of the promising drugs being developed nowadays is an anti-T SLIT [sublingual immunotherapy]. There are several of them, but one of them is in a phase 3 trial. That may actually be very promising in a way that may work in both T2 and non-T2 asthma.
But there are unmet needs, obviously. We don't have many targets for non-T2 asthma, which maybe constitutes about 40% of all asthmatics out there.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
